Clinical Trial Update: Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing 72-hour Iloprost infusion versus placebo in COVID-19 patients with respiratory failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Failure

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: Pär Johansson | Conditions: COVID-19, Respiratory Failure | Phase 2 | Status: COMPLETED